Scholarlink

<p>Thyroid cancer represents the ninth most common malignancy worldwide, and a subset of cases exhibits aggressive behaviour with limited therapeutic options. Fucoidan, a sulphated polysaccharide, has demonstrated anticancer activity with an undefined mechanism. Here, we investigated the biological effects of fucoidan (FU) and fucoidan nanoaggregates (NFU) in both thyroid cancer (SW1736) and non-tumorigenic thyroid cells (Nthy-ori 3.1). NFU showed a mean diameter of ~ 187&#xa0;nm, a low polydispersity (~ 0.2) and a negative Zeta potential. NFU significantly reduced SW1736 cell viability, reaching ~ 60% inhibition at 0.01&#xa0;mg/mL and ~ 80% at 0.1&#xa0;mg/mL after 72&#xa0;h, while sparing non-tumorigenic cells. Mechanistically, NFU induced marked lysosomal enlargement selectively in tumor cells and localized predominantly within LAMP-1–positive compartments. Consistently, tumor cells showed constitutive Cathepsin D maturation and enhanced sensitivity to NFU-induced lysosomal perturbation. Collectively, these findings identify lysosomes as a primary intracellular target of fucoidan-based nanosystems and reveal a tumor-selective vulnerability to NFU-mediated lysosomal stress. This study provides the first quantitative evidence of lysosomal targeting by fucoidan nanoparticles in thyroid cancer cells and supports NFU as a promising lysosome-directed nanotherapeutic strategy for aggressive thyroid malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lysosomal vulnerability as a therapeutic target in thyroid cancer using fucoidan nanoparticles

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Marilena Celano,
  • Agnese Gagliardi,
  • Raffaella Gallo,
  • Elena Giuliano,
  • Diego Russo,
  • Donato Cosco,
  • Giuseppe Fiume

摘要

Thyroid cancer represents the ninth most common malignancy worldwide, and a subset of cases exhibits aggressive behaviour with limited therapeutic options. Fucoidan, a sulphated polysaccharide, has demonstrated anticancer activity with an undefined mechanism. Here, we investigated the biological effects of fucoidan (FU) and fucoidan nanoaggregates (NFU) in both thyroid cancer (SW1736) and non-tumorigenic thyroid cells (Nthy-ori 3.1). NFU showed a mean diameter of ~ 187 nm, a low polydispersity (~ 0.2) and a negative Zeta potential. NFU significantly reduced SW1736 cell viability, reaching ~ 60% inhibition at 0.01 mg/mL and ~ 80% at 0.1 mg/mL after 72 h, while sparing non-tumorigenic cells. Mechanistically, NFU induced marked lysosomal enlargement selectively in tumor cells and localized predominantly within LAMP-1–positive compartments. Consistently, tumor cells showed constitutive Cathepsin D maturation and enhanced sensitivity to NFU-induced lysosomal perturbation. Collectively, these findings identify lysosomes as a primary intracellular target of fucoidan-based nanosystems and reveal a tumor-selective vulnerability to NFU-mediated lysosomal stress. This study provides the first quantitative evidence of lysosomal targeting by fucoidan nanoparticles in thyroid cancer cells and supports NFU as a promising lysosome-directed nanotherapeutic strategy for aggressive thyroid malignancies.